Daiwa Securities Group’s AbCellera Biologics ABCL Stock Holding History

Daiwa Securities Group’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.78M	Buy	327,600 +16,100	+5%	+$153K	0.01%	515
2026 Q2	$2.45M	Buy	+311,500	New	+$1.52M	﹤0.01%	653
2026 Q1	–	Sell	-1,151	Closed	-$4K	–	1177
2025 Q4	$4K	Hold	1,151	–	–	﹤0.01%	1248
2025 Q3	$6K	Hold	1,151	–	–	﹤0.01%	1185
2025 Q2	$4K	Hold	1,151	–	–	﹤0.01%	1161
2025 Q1	$3K	Hold	1,151	–	–	﹤0.01%	1157
2024 Q4	$3K	Hold	1,151	–	–	﹤0.01%	1184
2024 Q3	$3K	Hold	1,151	–	–	﹤0.01%	1193
2024 Q2	$3K	Hold	1,151	–	–	﹤0.01%	1221
2024 Q1	$5K	Hold	1,151	–	–	﹤0.01%	1200
2023 Q4	$7K	Hold	1,151	–	–	﹤0.01%	1184
2023 Q3	$5K	Hold	1,151	–	–	﹤0.01%	1150
2023 Q2	$7K	Hold	1,151	–	–	﹤0.01%	1153
2023 Q1	$9K	Hold	1,151	–	–	﹤0.01%	1113
2022 Q4	$12K	Buy	1,151 +91	+9%	+$1.05K	﹤0.01%	1103
2022 Q3	$10K	Hold	1,060	–	–	﹤0.01%	1124
2022 Q2	$11K	Buy	1,060 +238	+29%	+$2.02K	﹤0.01%	1135
2022 Q1	$8K	Hold	822	–	–	﹤0.01%	1146
2021 Q4	$12K	Buy	+822	New	+$12.5K	﹤0.01%	1139

Other funds holding ABCL

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

J.W. Cole Advisors Tampa, Florida $5.93B AUM 23.96% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Daiwa Securities Group's ABCL Position: Q3 2026 in Review

Daiwa Securities Group increased its AbCellera Biologics (ABCL) stake by 5.2% in Q3 2026, buying an estimated $153K and bringing the position to 327,600 shares worth $4.78M. The position accounts for 0.01% of the portfolio, ranked #515.

Daiwa Securities Group first reported a position in ABCL in Q4 2021 and has held it in 19 quarters since. 49 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

Daiwa Securities Group held 327,600 shares of AbCellera Biologics worth $4.78M as of Q3 2026.
Daiwa Securities Group bought 16,100 AbCellera Biologics shares in Q3 2026, an estimated $153K.
AbCellera Biologics made up 0.01% of Daiwa Securities Group's portfolio in Q3 2026, its #515 holding.
Daiwa Securities Group first reported a position in AbCellera Biologics in Q4 2021 and has held it in 19 quarters since.
49 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Daiwa Securities Group's 13F filing for Q3 2026, filed 29 Oct 2026.